masquerade or charade?, page-7

Andrewk65, do you seriously believe that Janssen would maneuver to:

- Promote a Phylogica capital raising by implying a deal was in the offing;

- String along the development, once the capital was in place; with the implication that:

- They will dump the project once the development has achieved milestones.

I have no doubt that Janssen is a serious partner and that their goals and objectives are more clearly understood by applying commercial logic:

- The EET is their delivery technology for an undisclosed payload;

- We do not know if the payload is a Phylomer or if it is a Janssen development - however, it does not really matter because the delivery technology is the really valuable thing (and currently, Phylogical owns this).

Valuing Phylogica depends on a deep understanding of the value of their technologies. Price action on the stock exchange is not a factor in the objective assesment of this technology.

The traders got on board to drive the price from about 1.5c to 3.8c. The traders took their profits. I see nothing fundamental in this little side show.